Literature DB >> 6147456

Specific chemical dissociation of fibrillar and non-fibrillar components of amyloid deposits.

C R Hind, P M Collins, D Caspi, M L Baltz, M B Pepys.   

Abstract

In systemic amyloidosis, a fatal disorder for which there is no effective treatment, the extracellular protein deposits are composed of amyloid fibrils together with a non-fibrillar glycoprotein, amyloid P component (AP). Methyl 4,6-O-(1-carboxyethylidene)-beta-D-galactopyranoside (MO beta DG), a recently identified ligand for AP, was tested for its ability to produce in-vitro elution of AP which had been laid down with amyloid fibrils in vivo. Millimolar concentrations of MO beta DG completely dissociated AP from human and murine splenic amyloid deposits. Availability of this material thus provides for the first time the opportunity for specific molecular dissection of amyloid deposits. If MO beta DG or a related substance were effective in vivo it might be of therapeutic importance.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6147456     DOI: 10.1016/s0140-6736(84)90544-0

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  10 in total

Review 1.  Amyloid accomplices and enforcers.

Authors:  Andrei T Alexandrescu
Journal:  Protein Sci       Date:  2004-12-02       Impact factor: 6.725

2.  Studies in vivo and in vitro of serum amyloid P component in normals and in a patient with AA amyloidosis.

Authors:  P N Hawkins; G A Tennent; P Woo; M B Pepys
Journal:  Clin Exp Immunol       Date:  1991-05       Impact factor: 4.330

Review 3.  Free radical involvement in aging. Pathophysiology and therapeutic implications.

Authors:  D Harman
Journal:  Drugs Aging       Date:  1993 Jan-Feb       Impact factor: 3.923

4.  Serum amyloid P component prevents proteolysis of the amyloid fibrils of Alzheimer disease and systemic amyloidosis.

Authors:  G A Tennent; L B Lovat; M B Pepys
Journal:  Proc Natl Acad Sci U S A       Date:  1995-05-09       Impact factor: 11.205

5.  Human serum amyloid P component is an invariant constituent of amyloid deposits and has a uniquely homogeneous glycostructure.

Authors:  M B Pepys; T W Rademacher; S Amatayakul-Chantler; P Williams; G E Noble; W L Hutchinson; P N Hawkins; S R Nelson; J R Gallimore; J Herbert
Journal:  Proc Natl Acad Sci U S A       Date:  1994-06-07       Impact factor: 11.205

6.  Circulating serum amyloid P component is the precursor of amyloid P component in tissue amyloid deposits.

Authors:  M L Baltz; D Caspi; D J Evans; I F Rowe; C R Hind; M B Pepys
Journal:  Clin Exp Immunol       Date:  1986-12       Impact factor: 4.330

7.  The pentraxins, C-reactive protein and serum amyloid P component, are cleared and catabolized by hepatocytes in vivo.

Authors:  W L Hutchinson; G E Noble; P N Hawkins; M B Pepys
Journal:  J Clin Invest       Date:  1994-10       Impact factor: 14.808

Review 8.  Microvascular pathology and vascular basement membrane components in Alzheimer's disease.

Authors:  L S Perlmutter
Journal:  Mol Neurobiol       Date:  1994 Aug-Dec       Impact factor: 5.590

9.  Pharmacological removal of serum amyloid P component from intracerebral plaques and cerebrovascular Aβ amyloid deposits in vivo.

Authors:  Raya Al-Shawi; Glenys A Tennent; David J Millar; Angela Richard-Londt; Sebastian Brandner; David J Werring; J Paul Simons; Mark B Pepys
Journal:  Open Biol       Date:  2016-02       Impact factor: 6.411

Review 10.  The Pentraxins 1975-2018: Serendipity, Diagnostics and Drugs.

Authors:  Mark B Pepys
Journal:  Front Immunol       Date:  2018-10-16       Impact factor: 7.561

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.